Integration of network pharmacology, metabolomics and lipidomics for clarifying the role of sphingolipid metabolism in the treatment of liver cancer by regorafenib
Sphingolipids, particularly dhCer and regulatory enzymes, may be potential sensitive markers of regorafenib in the treatment of liver cancer, providing new insights for enhancing the treated efficacy of regorafenib in liver cancer.
Authors
- Guowang Xu
- Zhikun Lin (ORCID: https://orcid.org/0000-0002-4555-4942)
- Chunxiu Hu (ORCID: https://orcid.org/0000-0002-4335-9895)
- Wenru Liu (ORCID: https://orcid.org/0000-0002-8285-5752)
- Hua Mu
- Jinlong Hu
- Rui Zhong (ORCID: https://orcid.org/0000-0003-4570-0927)
- Guang Tan (ORCID: https://orcid.org/0000-0002-0658-8867)
- Letian Wei
- Shimeng Cui (ORCID: https://orcid.org/0000-0001-7270-1699)
- Qi Li (ORCID: https://orcid.org/0000-0003-2120-2261)
- Pengyu Geng
- Xiaolin Wang
Institutions
- Dalian Institute of Chemical Physics (CN)
- Dalian Medical University (CN)
- Chinese Academy of Sciences (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- First Affiliated Hospital of Dalian Medical University (CN)
Publication Details
- Journal
- Life Sciences
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1016/j.lfs.2024.123165
- Citations
- 5
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.93